Insulet Corporation

PODD Healthcare Medical Devices

Insulet Corporation’s revenue for fiscal 2025 (year ended December 2025) was $2.7 billion, up 30.7% from fiscal 2024. In the quarter to June 2026, revenue grew 23.5%, EPS grew 328.1%, free cash flow fell 70.5% and total debt fell 32.2%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.

141.10 2.33 +1.68%
Market cap
$9.6B
P/E
26.4×
Fwd P/E
24.7×
Dividend yield
—
F-score
6/9
Altman Z
9.09
Beneish M
−2.59
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

6 6 6 9
ROE
19.68% 18.12% 23.00% 26.02%
ROA
8.13% 7.87% 9.31% 11.31%
ROIC
16.64% 16.94% 17.90% 17.56%
Return on Tangible Assets
12.72% 12.03% 16.35% 19.11%
Average Days of Receivables
66.90 69.67 68.54 70.37
Free Cash Flow per Share
5.79 4.97 5.54 3.83
Free Cash Flow
407.50 349.90 387.80 265.60
Capital Expenditures
(126.00) (219.40) (231.50) (245.60)
Other line items
Cash ROIC
12.91% 11.00% 14.20% 9.14%
Accounts Receivable Turnover
6.02 6.14 6.13 5.91
Accounts Payable Turnover
16.26 16.21 8.11 8.05
Inventory Turnover
1.61 1.74 1.86 1.90
Average Days of Payables
24.45 35.64 65.01 50.96
Days of Inventory on Hand
226.38 215.05 200.73 200.35
Tax Rate
(0.21) (0.27) (0.25) (0.24)
Research and Development Expense of Revenue
10.74% 11.12% 11.42% 11.33%
Selling, General and Administrative Expense of Revenue
43.40% 43.02% 42.11% 42.86%
Share Based Compensation of Revenue
2.47% 2.32% 2.27% 2.55%
Interest Coverage
8.25 7.98 7.81 8.77
Operating CF/Net income
2.17 2.30 2.05 1.36
Depreciation/Fixed assets
0.12 0.11 0.11 0.12
Capex/Depreciation
(1.44) (2.43) (2.44) (2.47)
Revenue per Share
35.84 38.50 41.45 44.06
Operating CF per Share
7.58 8.09 8.85 7.38
Capex per Share
(1.79) (3.12) (3.31) (3.54)
Capex to Sales
0.05 0.08 0.08 0.08

Fold the line items

Columns are period end dates